As the global Covid-19 pandemic enters its third year, life science innovation is setting new records in the level of investment, activity and scientific progress, in addition to the number and range of new medicines reaching patients around the world. Beyond the ground-breaking contributions to Covid-19 in the form of vaccines and therapeutics, this sector has also succeeded in adapting and re-focusing to a remarkable extent, overcoming the many operational and organisational challenges.